Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay

Claim 2

An immunometric assay for detecting the presence of prostatic acid phosphatase and prostate antigen in a sample which comprises contacting the sample with (a) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8523, which is directed against prostatic acid phosphatase, (b) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8525, which is directed against prostate antigen, (c) an immobilized monoclonal antibody from hybridoma cell line ATCC No. HB 8526 or HB 8523, directed against prostatic acid phosphatase, and (d) an immobilized monoclonal antibody from hybridoma cell line ATCC No. HB 8527, directed against prostate antigen, wherein each immobilized antibody is immobilized on a common support.

Claim 3

The assay of claim 1 wherein the label or labels are selected from the group consisting of enzymes, radioactive isotopes and fluorescent compounds.

Claim 4

The assay of claim 1 wherein the labels on each monoclonal antibody are the same.

Claim 5

The assay of claim 1 wherein the labels on each monoclonal antibody are different.

Claim 6

The assay of claim 1 wherein the sample is a body fluid.

Claim 7

The assay of claim 1 wherein the immobilized antibodies are immobilized on polystyrene beads.

Claim 8

The process of claim 1 wherein the immobilized antibody against prostatic acid phosphatase is from HB 8526.

Claim 9

A direct immunometric assay for detecting the presence of prostatic acid phosphatase and prostate antigen in a sample which comprises: (a) incubating the sample with an immobilized monoclonal antibody from hybridoma cell line ATCC No. HB 8523, which is directed against prostatic acid phosphatase, and with an immobilized monoclonal antibody from hybridoma cell line ATCC No. HB 8525, which is directed against prostate antigen, wherein both antibodies are immobilized on a common support and wherein if both prostatic acid phosphatase and prostate antigen are present, each of the immobilized antibodies will complex with its corresponding antigen; (b) incubating the incubation product of step (a) with (i) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8526 or HB 8523, directed against prostatic acid phosphatase, and (ii) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8527, directed against prostate antigen, wherein if both prostatic acid phosphatase and prostate antigen are present, each of the labeled antibodies will complex with its corresponding antigen; (c) detecting the amount of labeled antibodies associated with the incubation product of step (b) or the amount of unassociated labeled antibodies; and (d) determining the amount of antigens in the sample from the amount of labeled antibodies detected from step (c).

Claim 10

A direct immunometric assay for detecting the presence of prostatic acid phosphatase and prostate antigen in a sample which comprises: (a) incubating the sample with an immobilized monoclonal antibody from hybridoma cell line ATCC No. HB 8523, which is directed against prostatic acid phosphatase, and with an immobilized monoclonal antibody from hybridoma cell line ATCC No. HB 8525, which is directed against prostate antigen, wherein both antibodies are immobilized on a common support and wherein if both prostatic acid phosphatase and prostate antigen are present, each of the immobilized antibodies will complex with its corresponding antigen; (b) incubating the incubation product of step (a) with (i) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8526 or HB 8523, directed against prostatic acid phosphatase, and (ii) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8527, directed against prostate antigen, wherein if both prostatic acid phosphatase and prostate antigen are present, each of the labeled antibodies will complex with its corresponding antigen; (c) detecting the amount of labeled antibodies associated with the incubation product of step (b) or the amount of unassociated labeled antibodies; and (d) determining the amount of antigens in the sample from the amount of labeled antibodies detected from step (c).

Claim 11

The assay of claim 8 wherein at least one label is selected from the group consisting of enzymes, radioactive isotopes and fluorescent compounds.

Claim 12

The assay of claim 8 wherein the immobilized antibody against prostatic acid phosphatase is from HB 8626.

Claim 13

An immunometric assay for detecting the presence of prostatic acid phosphatase and prostate antigen in a sample which comprises: (a) forming a complex of (1) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8523, which is directed against prostatic acid phosphatase and is complexed to (2) prostatic acid phosphatase, which is in turn complexed to (3) an unlabeled monoclonal antibody from hybridoma cell line ATCC No. HB 8523 or HB 8526 whichis directed against prostatic acid phosphatase and immobilized on a support to which is also immobilized (4) an unlabeled monoclonal antibody from hybridoma cell ATCC No. HB 8527, which is directed against prostate antigen and is complexed to (5) prostate antigen, which is in turn complexed to (6) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8525, which is directed against prostate antigen; and (b) measuring either the amount of labeled antibodies bound to the complex or the amount of unbound labeled antibodies to detect the presence of prostatic acid phosphatase and prostate antigen in the sample.

Claim 14

An immunometric assay for detecting the presence of prostatic acid phosphatase and prostate antigen in a sample which comprises: (a) forming a complex of (1) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8523, which is directed against prostatic acid phosphatase and is complexed to (2) prostatic acid phosphatase, which is in turn complexed to (3) an unlabeled monoclonal antibody from hybridoma cell line ATCC No. HB 8523 or HB 8526 whichis directed against prostatic acid phosphatase and immobilized on a support to which is also immobilized (4) an unlabeled monoclonal antibody from hybridoma cell ATCC No. HB 8527, which is directed against prostate antigen and is complexed to (5) prostate antigen, which is in turn complexed to (6) a labeled monoclonal antibody from hybridoma cell line ATCC No. HB 8525, which is directed against prostate antigen; and (b) measuring either the amount of labeled antibodies bound to the complex or the amount of unbound labeled antibodies to detect the presence of prostatic acid phosphatase and prostate antigen in the sample.

Claim 15

The assay of claim 11 wherein the immobilized antibodies, antigens and labeled antibodies are incubated simultaneously to form the complex.

Claim 16

The assay of claim 11 wherein the immobilized antibody against prostatic acid phosphatase is from HB 8526.

Claim 17

A test kit for conducting an immunometric assay for detecting the presence of prostatic acid phosphatase and prostate antigen in a sample, which comprises, in packaged combination, a multicontainer unit having: (a) a first container containing a monoclonal antibody from hybridoma cell line ATCC No. HB 8523 directed against prostatic acid phosphatase and separately conjugated to a label; (b) a second container containing a monoclonal antibody from hybridoma cell line ATCC No. 8525 directed against prostate antigen and separately conjugated to a label; and (c) a third container containing a single support on which is immobilized an unlabeled monoclonal antibody from hybridoma cell line ATCC No. HB 8523 or HB 8526 directed against prostatic acid phosphatase, and an unlabeled monoclonal antibody from hybridoma cell line ATCC No. HB 8527, directed against prostate antigen.

Claim 18

A test kit for conducting an immunometric assay for detecting the presence of prostatic acid phosphatase and prostate antigen in a sample, which comprises, in packaged combination, a multicontainer unit having: (a) a first container containing a monoclonal antibody from hybridoma cell line ATCC No. HB 8523 directed against prostatic acid phosphatase and separately conjugated to a label; (b) a second container containing a monoclonal antibody from hybridoma cell line ATCC No. 8525 directed against prostate antigen and separately conjugated to a label; and (c) a third container containing a single support on which is immobilized an unlabeled monoclonal antibody from hybridoma cell line ATCC No. HB 8523 or HB 8526 directed against prostatic acid phosphatase, and an unlabeled monoclonal antibody from hybridoma cell line ATCC No. HB 8527, directed against prostate antigen.

Claim 19

The test kit of claim 14 wherein at least one label is selected from the group consisting of enzymes, radioactive isotopes and fluorescent compounds.

Claim 20

The test kit of claim 14 wherein the labels on each labeled monoclonal antibody are different.

Claim 21

The test kit of claim 14 wherein the immobilized antibody against prostatic acid phosphatase is from HB 8526.